Anti-diabetic effects of Protaetia brevitarsis in pancreatic islets and a murine diabetic model.
| Autor: | Park YM; INVIVO Co. Ltd., Iksan, Jeonbuk, Korea. jsbae78@wku.ac.kr., Noh EM, Lee HY, Shin DY, Lee YH, Kang YG, Na EJ, Kim JH, Yang HJ, Kim MJ, Kim KS, Bae JS, Lee YR |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | European review for medical and pharmacological sciences [Eur Rev Med Pharmacol Sci] 2021 Dec; Vol. 25 (23), pp. 7508-7515. |
| DOI: | 10.26355/eurrev_202112_27450 |
| Abstrakt: | Objective: In this study, the antidiabetic efficacy of Protaetia brevitarsis in alloxan-treated pancreatic islets and db/db mice was investigated. P. brevitarsis was tested for alloxan-mediated cytotoxicity and nitric oxide production in mice pancreatic islets. Materials and Methods: The anti-diabetic effect of P. brevitarsis was also evaluated in db/db mice after 4 weeks of administration. Biochemical analysis, oral glucose tolerance test (OGTT), and pancreatic histological analysis were performed. Results: P. brevitarsis displayed hypoglycemic activity in alloxan-treated mice pancreatic islets. Our results showed that P. brevitarsis protects pancreatic islets from cytotoxicity. Moreover, daily oral supplementation with P. brevitarsis for 4 weeks reduced plasma glucose levels without affecting body weight and food intake, elevated glucose tolerance in OGTT, improved blood lipid parameters, inhibited fat accumulation, and restored islet structure of db/db mice. Conclusions: The present study provided evidence for the anti‑diabetic effect of P. brevitarsis in alloxan-treated pancreatic islets and db/db mice. These results suggest that P. brevitarsis may be used as an adjunctive anti-diabetic agent or as a functional food. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|